Over the last 7 days, the United States market has experienced a 2.3% decline, yet it remains up by 21% over the past year with earnings projected to grow by 19% annually in the coming years. In this context, identifying high growth tech stocks involves looking for companies with strong innovation and scalability potential that can thrive despite short-term market fluctuations.

Top 10 High Growth Tech Companies In The United States

Name	Revenue Growth	Earnings Growth	Growth Rating
AppLovin	21.41%	21.98%	★★★★★★
Krystal Biotech	29.15%	36.59%	★★★★★★
Reddit	21.88%	25.35%	★★★★★★
Fabrinet	21.38%	23.34%	★★★★★★
Sandisk	39.64%	36.56%	★★★★★★
Palantir Technologies	30.88%	31.93%	★★★★★★
Marker Therapeutics	64.28%	69.04%	★★★★★★
Zscaler	14.29%	55.86%	★★★★★☆
Intellia Therapeutics	55.83%	67.02%	★★★★★☆
Circle Internet Group	21.50%	49.04%	★★★★★☆

Let's explore several standout options from the results in the screener.

Clearfield (CLFD)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Clearfield, Inc. designs, manufactures, and distributes fiber management, protection, and delivery products globally with a market cap of $549.69 million.

Operations: Clearfield generates revenue primarily from its fiber management, protection, and delivery products, amounting to $148.55 million.

Clearfield's strategic partnerships and product innovations are positioning it strongly within the high-growth tech sector. Recently, the company expanded its collaboration with VoltServer to power 5G networks, highlighting its commitment to advancing telecom infrastructure. This move complements Clearfield's robust performance in deploying efficient fiber solutions in challenging environments like the British Virgin Islands, where their technology halved deployment times post-hurricane. Financially, despite a recent downturn with a Q2 net loss of $0.528 million from sales of $34.39 million, Clearfield is optimistic, projecting up to $46 million in sales next quarter. Their ongoing share repurchase program also reflects confidence in long-term value, having reacquired 18.75% of shares for $68.98 million since 2014.

Daktronics (DAKT)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Daktronics, Inc. is a company that designs, manufactures, and sells electronic scoreboards, programmable display systems, and large screen video displays for various applications across sporting, commercial, and transportation sectors globally; it has a market cap of approximately $1.01 billion.

Operations: The company generates revenue through segments such as Commercial ($181.01 million), Live Events ($295.79 million), International ($76.98 million), Transportation ($71.43 million), and High School Park and Recreation ($177.44 million).

Daktronics has demonstrated robust growth, with earnings surging by an impressive 2561.6% over the past year, significantly outpacing the electronic industry's average of 10.6%. This surge is primarily driven by strategic client installations like those at Yankee Stadium and Los Angeles International Airport, enhancing both experience and visibility. Despite a slower revenue growth forecast of 8.5% annually compared to the US market's 13%, Daktronics' earnings are expected to grow at a brisk pace of 36.5% per year, outstripping the US market projection of 18.9%. The company's commitment to innovation is underscored by substantial R&D investments totaling $13.7 million in non-recurring expenses last year, positioning it well for future technological advancements and market competitiveness.

Kiniksa Pharmaceuticals International (KNSA)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Kiniksa Pharmaceuticals International, plc is a biopharmaceutical company focused on developing and commercializing medical therapies across the United States, the United Kingdom, and internationally, with a market cap of approximately $4.40 billion.

Operations: Kiniksa Pharmaceuticals generates revenue primarily from developing and delivering therapeutic medicines, amounting to $754.05 million. The company's operations span the United States, the United Kingdom, and international markets.

Kiniksa Pharmaceuticals International has recently demonstrated a notable uptick in financial performance, with first-quarter revenue jumping to $214.27 million from $137.79 million year-over-year and net income rising to $22.59 million from $8.54 million. This surge aligns with an upward revision of their 2026 revenue forecast, now expected between $930 million and $945 million, reflecting robust market confidence and strategic operational efficiency. The company's significant investment in R&D is poised to fuel continued innovation, underscored by a high Return on Equity forecast at 23.5% in three years' time—well above industry benchmarks—which suggests strong future profitability potential amid competitive pressures within the biotech sector.

Taking Advantage

• Get an in-depth perspective on all 65 US High Growth Tech and AI Stocks by using our screener here.
• Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly.
• Elevate your portfolio with Simply Wall St, the ultimate app for investors seeking global market coverage.

Contemplating Other Strategies?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.